Huitai Medical to acquire remaining 37.33% stake in Shanghai Hongtong for 586M yuan

Huitai Medical plans to use 586 million yuan of its own funds to acquire the remaining 37.33% equity in its subsidiary Shanghai Hongtong from minority shareholders, making it a wholly owned subsidiary. The deal is based on a valuation of 1.569 billion yuan for Shanghai Hongtong.

“惠泰医疗(688617.SH)发布公告，公司拟使用自有资金5.86亿元人民币分两步收购控股子公司上海宏桐实业有限公司(简称“上海宏桐”)少数股东张向梅、张勇、沈海东、谷双全、肖昆、吴琦、王伏龙、刘宇、张纯逸9人合计持有的上海宏桐37.33%股权。”beta.zhitongcaijing.com

• 1 source
• beta.zhitongcaijing.com惠泰医疗(688617.SH)拟以5.86亿元收购少数股东合计持有的上海宏桐37.33%股权Jun 14, 2022

Summarized from public sources; check the original articles before acting on it.